---
layout: default
title: Ritonavir
description: "Ritonavir çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 149
evidence_level: L2
indication_count: 3
---

# Ritonavir

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ritonavirï¼šå¾ HIV åˆ°çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’æ„ŸæŸ“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ritonavir å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ritonavir æ˜¯ä¸€ç¨® HIV è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’æ„ŸæŸ“ (Simian Immunodeficiency Virus Infection)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | HIV infectious diseaseã€simian immunodeficiency virus infectionã€feline acquired immunodeficiency syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.92% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. simian immunodeficiency virus infection</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.92%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Ritonavir æ˜¯ä¸€ç¨® HIV è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼Œä¸»è¦ç”¨æ–¼ HIV æ²»ç™‚ã€‚ç›®å‰å®ƒé€šå¸¸ä½œç‚ºè—¥ç‰©å‹•åŠ›å­¸å¢å¼·åŠ‘ï¼ˆboosterï¼‰èˆ‡å…¶ä»–è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ darunavirã€lopinavirï¼‰ä½µç”¨ï¼Œä»¥æé«˜å…¶ä»–è—¥ç‰©çš„è¡€ä¸­æ¿ƒåº¦ã€‚</p>

<p>çŒ¿å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆSIVï¼‰æ˜¯ HIV çš„è¿‘è¦ªç—…æ¯’ï¼Œåœ¨éäººéˆé•·é¡å‹•ç‰©ä¸­å¼•èµ·é¡ä¼¼ AIDS çš„ç–¾ç—…ã€‚SIV æ˜¯ç ”ç©¶ HIV æ„ŸæŸ“å’ŒæŠ—ç—…æ¯’è—¥ç‰©çš„é‡è¦å‹•ç‰©æ¨¡å‹ã€‚ç”±æ–¼ SIV å’Œ HIV çš„è›‹ç™½é…¶å…·æœ‰çµæ§‹ç›¸ä¼¼æ€§ï¼Œé‡å° HIV è›‹ç™½é…¶çš„æŠ‘åˆ¶åŠ‘å° SIV ä¹Ÿå¯èƒ½å…·æœ‰æ´»æ€§ã€‚</p>

<p>æ–‡ç»ç ”ç©¶å·²è­‰å¯¦ï¼š</p>
<ol>
<li>Ritonavir åœ¨é«”å¤–å° SIVmac239 å…·æœ‰æŠ‘åˆ¶æ´»æ€§</li>
<li>åŒ…å« ritonavir-boosted lopinavir çš„å¤šè—¥çµ„åˆç™‚æ³•å¯æœ‰æ•ˆæŠ‘åˆ¶ SIV æ„ŸæŸ“çš„æ†æ²³çŒ´é«”å…§ç—…æ¯’è¼‰é‡</li>
<li>SIV/SHIV å‹•ç‰©æ¨¡å‹æ˜¯è©•ä¼°æŠ—é€†è½‰éŒ„ç—…æ¯’è—¥ç‰©çš„é‡è¦å·¥å…·</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16973590/" target="_blank">16973590</a></td><td>2006</td><td>Article</td><td>Journal of virology</td><td>Rapid viral decay in simian immunodeficiency virus-infected macaques receiving q...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12709355/" target="_blank">12709355</a></td><td>2003</td><td>Article</td><td>Antimicrobial agents and chemo</td><td>Susceptibilities of simian immunodeficiency virus to protease inhibitors.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34903055/" target="_blank">34903055</a></td><td>2021</td><td>Article</td><td>mBio</td><td>Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17350308/" target="_blank">17350308</a></td><td>2007</td><td>Article</td><td>Microbes and infection</td><td>Construction of a novel SHIV having an HIV-1-derived protease gene and its infec...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25033210/" target="_blank">25033210</a></td><td>2014</td><td>Article</td><td>PloS one</td><td>Effects of treatment with suppressive combination antiretroviral drug therapy an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15040537/" target="_blank">15040537</a></td><td>2004</td><td>Article</td><td>Antiviral therapy</td><td>Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implicati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11364629/" target="_blank">11364629</a></td><td>1997</td><td>Article</td><td>Journal of the International A</td><td>Pouncing on the chemokine receptor Chimera.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9875393/" target="_blank">9875393</a></td><td>1998</td><td>Article</td><td>Antiviral chemistry &amp; chemothe</td><td>Broad-spectrum antiviral activity and mechanism of antiviral action of the fluor...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22737073/" target="_blank">22737073</a></td><td>2012</td><td>Article</td><td>PLoS pathogens</td><td>A highly intensified ART regimen induces long-term viral suppression and restric...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12951220/" target="_blank">12951220</a></td><td>2003</td><td>Article</td><td>Journal of virological methods</td><td>The impact of highly active antiretroviral therapy by the oral route on the CD8 ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12186895/" target="_blank">12186895</a></td><td>2002</td><td>Article</td><td>Journal of virology</td><td>Intravirion processing of the human immunodeficiency virus type 1 Vif protein by...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7475727/" target="_blank">7475727</a></td><td>1995</td><td>Article</td><td>Lancet (London, England)</td><td>Update on HIV transmission and pathogenesis.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. feline acquired immunodeficiency syndrome</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02770508" target="_blank">NCT02770508</a></td><td>PHASE4</td><td>COMPLETED</td><td>145</td><td>A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lam...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | æ™®åˆ©ä»–è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | äººé¡å…ç–«ç¼ºä¹ç—…æ¯’ï¼ˆHIVï¼‰æ„ŸæŸ“ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è—¥ç‰©äº¤äº’ä½œç”¨ï¼šRitonavir æ˜¯ CYP3A4 çš„å¼·æ•ˆæŠ‘åˆ¶åŠ‘ï¼Œèˆ‡å¤šç¨®è—¥ç‰©æœ‰é¡¯è‘—äº¤äº’ä½œç”¨
- è‚æ¯’æ€§
- è„‚è³ªä»£è¬ç•°å¸¸

**ç¦å¿Œç—‡ï¼š**
è«‹åƒè€ƒåŸå» ä»¿å–®




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©å¸æ”¶ã€‚å¯èƒ½é™ä½è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šè«‹è«®è©¢é†«å¸«æˆ–è—¥å¸«äº†è§£è©³ç´°å»ºè­°ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é¡¯è‘—é™ä½ Ritonavir è¡€ä¸­æ¿ƒåº¦ï¼Œå¯èƒ½å°è‡´ HIV æ²»ç™‚å¤±æ•—
- å»ºè­°ï¼šçµ•å°ç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Hyperglycemia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Heart Block** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šRitonavir may prolong the PR interval in some patients...

**Hemophilia A** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè‚æ¯’æ€§ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é€™å€‹é æ¸¬åœ¨ç§‘å­¸ä¸Šæ˜¯åˆç†çš„ï¼Œå› ç‚º SIV æ˜¯ HIV çš„è¿‘è¦ªç—…æ¯’ï¼Œritonavir å° SIV è›‹ç™½é…¶çš„æŠ‘åˆ¶æ´»æ€§å·²åœ¨é«”å¤–å’Œå‹•ç‰©æ¨¡å‹ä¸­å¾—åˆ°è­‰å¯¦ã€‚ç„¶è€Œï¼Œç”±æ–¼ SIV ä¸æ„ŸæŸ“äººé¡ï¼Œé€™å€‹é æ¸¬çš„ä¸»è¦æ‡‰ç”¨æ˜¯åœ¨ç¸é†«å­¸é ˜åŸŸï¼ˆéˆé•·é¡å‹•ç‰©ï¼‰æˆ–ä½œç‚º HIV ç ”ç©¶çš„å‹•ç‰©æ¨¡å‹å·¥å…·ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€™ä¸»è¦æ˜¯ç¸é†«å­¸/å‹•ç‰©ç ”ç©¶çš„æ‡‰ç”¨
- è©•ä¼°åœ¨ SIV æ„ŸæŸ“çš„éäººéˆé•·é¡å‹•ç‰©ä¸­çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§
- ä½œç‚º HIV ç ”ç©¶å·¥å…·ï¼Œå·²æœ‰å……åˆ†çš„æ‡‰ç”¨åŸºç¤
- å°æ–¼è²“æ„›æ»‹ç—…ï¼ˆFIVï¼‰ï¼Œéœ€é€²è¡Œé¡å¤–çš„ç¨®é–“äº¤å‰åæ‡‰ç ”ç©¶

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Vismodegib]({{ "/drugs/vismodegib/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Aluminum Oxide]({{ "/drugs/aluminum_oxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Salicylamide]({{ "/drugs/salicylamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ritonavirè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ritonavir/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ritonavir,
  title = {Ritonavirè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ritonavir/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
